Status: Recruiting
Immune Modulation by Exosomes in COVID-19
Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.
Participants needed: 40
Trial details
Age: 18-90Biological sex: AllType: ObservationalSponsor: University of UlmUpdated: Jan 17, 2024Locations: 1Duration: 12 Months
Eligibility criteria
Critically ill COVID-19 patients with lung dysfunction [+3]
Pregnant or breast feeding women